PADCEV plus Keytruda reduces bladder cancer recurrence risk by 47%

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. GOOGL
6. RTX
7. COF
8. SMCI
9. TSLA
10. BRZE

Go back to PADCEV plus Keytruda reduces bladder cancer recurrence risk by 47%

PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer

February 27, 2026 10:00 AM EST

In the Phase 3 EV-304 trial, statistically significant improvements in overall survival and pathological complete response were also observed, with over half of patients having no detectable disease at surgery The results, combined with the recent unprecedented data from the EV-303 trial,... More